SCODiA Report by MLBI Lab

Single-Cell Transcriptomic Atlas of Colonic Inflammation: Cellular Reprogramming, Intercellular Communication, and Therapeutic Implications

This report presents a single-cell transcriptomic analysis of human colon tissue, elucidating the cellular and molecular landscape of colonic inflammation. Key findings reveal significant shifts in immune cell populations, including the infiltration and activation of B cells, T cells, ILCs, and a polarization of macrophages towards a pro-inflammatory M1-like state. Intercellular communication networks are profoundly altered, driving inflammatory responses and extensive reprogramming of intestinal epithelial cells and fibroblasts, which actively contribute to inflammation, tissue remodeling, and fibrosis. The presence of activated immune and stromal cells and inflammatory pathway enrichment in 'Non-inflamed' samples suggests subclinical inflammation or persistent immune alterations beyond overt disease.

Contents

  1. Dataset overview
  2. UMAP Visualization of Colon Single-Cell RNA-seq Data by Condition, Sample, and Cell Type Hierarchies
  3. Major Cell Type Score Visualization on UMAP
  4. Marker Expression Profiles Across Colon Cell Subsets
  5. Analysis of Minor Cell Type Population Distribution in Colonic Inflammation
  6. T cell and Innate Lymphoid Cell Subpopulation Analysis in Colonic Inflammation
  7. T cell Subset Population Shifts in Colonic Inflammation
  8. Macrophage Subset Population Shifts in Colonic Inflammation
  9. Macrophage (M2B) Subset Population Dynamics in Colonic Inflammation
  10. Cell-Cell Interaction Patterns in Healthy, Inflamed, and Non-inflamed Colon
  11. Cell-Cell Interaction Patterns in Colonic Inflammation
  12. Condition-Specific Surfaceome Markers in Intestinal Epithelial Cells During Colonic Inflammation
  13. Macrophage Condition-Specific Surfaceome Markers in Colonic Inflammation
  14. Fibroblast Condition-Specific Surfaceome Markers in Colonic Inflammation
  15. Condition-Specific Surfaceome Markers in Colonic CD4+ T Cells
  16. Gene Ontology (GSA) Analysis for Intestinal Epithelial Cells in Colonic Conditions
  17. Gene Set Enrichment Analysis (GSEA) Across Colon Cell Types in Inflammatory Conditions
  18. Discussion
  19. Query List

0. Dataset overview

Dataset Summary

Precomputed Results: The dataset includes precomputed results for

1. UMAP Visualization of Colon Single-Cell RNA-seq Data by Condition, Sample, and Cell Type Hierarchies

Report figure

[Analysis Visualization Results]...

Analysis Overview

This analysis presents Uniform Manifold Approximation and Projection (UMAP) plots generated from single-cell RNA-seq data of human colon tissue. These UMAPs visualize the cellular landscape colored by various metadata features: experimental condition (Healthy, Inflamed, Non-inflamed), individual sample origin, and hierarchical cell type annotations (major, minor, and subset levels). The primary goal is to assess the overall data structure, identify potential batch effects, and evaluate the quality of cell type annotation across different levels of granularity.

Visual Summary

Condition UMAP

The UMAP colored by condition reveals distinct patterns related to the inflammatory status of the colon tissue.

Sample UMAP

The UMAP colored by sample shows a generally good integration of data across different individuals.

Celltype_major UMAP

The UMAP colored by celltype_major demonstrates excellent separation of broad cell populations.

Celltype_minor UMAP

The celltype_minor UMAP provides a more granular view, showing sub-clustering within the major cell type regions.

Celltype_subset UMAP

The celltype_subset UMAP displays the highest level of resolution, showing a detailed landscape of specific cell subtypes.

Biological Interpretation

The UMAP visualizations collectively provide strong evidence for high-quality single-cell data processing and annotation in this human colon dataset.

  1. Cell Type Heterogeneity and Annotation Quality: The excellent separation of cells at major, minor, and subset levels confirms the robust identification and annotation of diverse cell populations in the colon. This level of resolution is crucial for dissecting complex biological processes like inflammation. The distinct clusters for epithelial cells (e.g., goblet, crypt, paneth) and immune cells (e.g., various T cell and macrophage subsets) are particularly important for studying colonic health and disease.
  2. Impact of Inflammation on Cellular Landscape: The condition UMAP suggests that colonic inflammation significantly alters the cellular composition and/or states. While "Inflamed" and "Non-inflamed" tissues share some cellular features, the existence of distinct "Healthy" clusters and condition-specific enrichments within "Inflamed" and "Non-inflamed" areas indicates a clear transcriptional divergence associated with disease. This implies that inflammatory processes reshape the cellular ecosystem of the colon, potentially driving shifts in cell proportions or inducing distinct cellular activation states.
  3. Data Integration and Batch Effects: The generally well-mixed sample UMAP indicates that the data integration methods were effective in mitigating strong sample-specific technical variations. This allows for more confident biological comparisons across conditions and cell types, as the observed differences are less likely to be artifacts of individual sample processing.

Annotation Notes

2. Major Cell Type Score Visualization on UMAP

Report figure

[Analysis Visualization Results]...

Analysis Overview

This analysis visualizes the distribution of major cell type scores across the Uniform Manifold Approximation and Projection (UMAP) embedding. Each plot displays the score for a specific major cell type, with higher scores (yellow/green) indicating a stronger transcriptional signature for that cell type in a given cell, and lower scores (purple) indicating a weaker or absent signature. The final UMAP plot shows the pre-assigned celltype_major annotations for comparison. This provides a critical visual assessment of the robustness and distinctness of the cell type classifications within the single-cell RNA-seq dataset of human Colon tissue.

Visual Summary

The UMAP plots effectively illustrate the spatial distribution and clustering of different major cell types based on their transcriptional profiles:

Biological Interpretation

The UMAP visualizations based on major cell type scores provide clear biological insights into the cellular landscape of the human colon. The distinct clustering of different cell types on the UMAP, strongly correlating with specific cell type scores, indicates robust cell identity definition within the dataset.

Annotation Notes

The strong concordance between the major cell type scores and the celltype_major annotations on the UMAP confirms the high quality and reliability of the cell type assignments in this dataset. The distinct, non-overlapping clusters for most major cell types, combined with their specific score enrichments, suggest that the clustering and annotation process has successfully resolved the major cellular identities.

3. Marker Expression Profiles Across Colon Cell Subsets

Report figure

[Analysis Visualization Results]...

Analysis Overview

This analysis presents a marker expression dot plot generated from single-cell RNA-seq data, visualizing the expression patterns of key genes across various celltype_subset populations found in the human colon. The plot serves as a critical tool for validating and refining cell type annotations. Each dot represents a gene-cell type pair, with its size indicating the fraction of cells within that group expressing the gene, and its color intensity reflecting the mean expression level of the gene. Red boxes highlight markers exhibiting high specificity for particular cell groups, reinforcing the confidence in their assigned identities.

Visual Summary

The dot plot demonstrates distinct and well-defined marker gene expression patterns across most of the 43 celltype_subset populations. A prominent diagonal pattern of large, darkly colored dots, often encircled by red boxes, signifies that many cell types are characterized by unique and highly specific gene signatures.

Epithelial Cell Lineages:

Stromal and Endothelial Cells:

Immune Cell Lineages:

Biological Interpretation

The marker gene expression patterns observed in the plot largely corroborate established biological identities of these diverse cell populations within the human colon.

Annotation Notes

The marker expression dot plot provides strong evidence for the accuracy and quality of the celltype_subset annotations within this single-cell dataset of the human colon. The consistent appearance of canonical, highly specific markers (indicated by large, dark red dots within red boxes) for most cell populations reinforces the confidence in their assigned identities.

The resolution of closely related cell types, such as different B cell or macrophage subsets, with both shared lineage markers and distinct differentiating markers, demonstrates the granular precision of the cell type assignments. This robust annotation is crucial for downstream analyses, especially when investigating condition-specific changes in inflammatory diseases of the colon, as it ensures that observed differential gene expression or pathway enrichment can be accurately attributed to specific cell populations. Only a few cell types, such as LTI, show less distinct marker enrichment within the selected top genes, suggesting that while their overall classification may be correct, their defining molecular features might be more nuanced or rely on markers not prominently displayed in this particular plot. Overall, the visualization strongly supports the validity of the celltype_subset annotations.

4. Analysis of Minor Cell Type Population Distribution in Colonic Inflammation

Report figure

[Analysis Visualization Results]...

Analysis Overview

This analysis presents population bar plots of minor cell types across individual samples, grouped by three conditions: Healthy, Inflamed, and Non-inflamed. Each bar represents a single sample, and the stacked segments within each bar show the proportional abundance of different minor cell types within that sample. This visualization provides insights into how the cellular composition of the colon tissue varies across different inflammatory states and among individual subjects.

Visual Summary

The stacked bar charts display the relative abundance of 15 minor cell types identified in the colon tissue, for samples categorized as Healthy (n=12), Inflamed (n=18), and Non-inflamed (n=18).

Biological Interpretation

The observed shifts in minor cell type populations strongly align with the biological context of Colonic Inflammation.

  1. Immune Cell Infiltration and Activation: The most striking feature is the substantial increase in various immune cell populations (B cells, Macrophages, Plasma cells, T cell CD4+, T cell CD8+) in 'Inflamed' samples compared to 'Healthy'. This is a hallmark of inflammation, where immune cells are recruited to the site of injury or infection to mount an immune response.
    • B cells and Plasma cells: The expansion of B cells and subsequent differentiation into Plasma cells (which produce antibodies) indicates active humoral immune responses within the inflamed colon. This is characteristic of chronic inflammatory conditions like Inflammatory Bowel Disease (IBD) PubMed search: B cells inflammatory bowel disease.
    • Macrophages: Macrophages are key effector cells in inflammation, involved in antigen presentation, cytokine production, and tissue remodeling. Their increased presence suggests ongoing inflammatory processes GeneCards: Macrophage.
    • T cells (CD4+ and CD8+): An increase in both CD4+ helper T cells and CD8+ cytotoxic T cells points to an activated adaptive immune response, which is central to the pathogenesis of many chronic inflammatory diseases in the gut PubMed search: T cells colonic inflammation.
  2. Epithelial Disruption: The relative decrease in Intestinal Epithelial cells in inflamed samples likely reflects several factors: dilution due to massive immune cell infiltration, epithelial damage, cell death, or alterations in epithelial cell differentiation under inflammatory stress. This is a common feature in conditions like IBD, where the epithelial barrier is often compromised.
  3. Heterogeneity in Non-inflamed Samples: The finding that some 'Non-inflamed' samples show an elevated immune cell burden, particularly B cells, is significant. This could indicate:
    • Subclinical inflammation: These individuals might have low-grade, undetected inflammation.
    • Remission states: Patients in remission from a previous inflammatory episode might still harbor an altered immune cell landscape compared to truly healthy individuals.
    • Variability in diagnostic criteria: The 'Non-inflamed' classification might encompass a broader range of states than a strictly 'Healthy' control group.
  4. Stability of Minor Structural Cells: The relatively stable proportions of other structural cells (e.g., Endothelial cells, Enteric glial cells, Fibroblasts, Smooth muscle cells) and some minor immune populations (e.g., Dendritic cells, ILC, NK cells) suggest that while immune infiltration is prominent, the underlying stromal and neuronal architecture might be proportionally less affected, or their changes are masked by the larger shifts in other populations.

Clinical or Translational Implications

The observed shifts in cell type populations have several potential clinical and translational implications for colonic inflammation:

  1. Biomarkers of Disease Activity: The proportional increase in specific immune cell types, particularly B cells, Macrophages, Plasma cells, and T cells, could serve as robust cellular biomarkers for identifying active inflammation or assessing disease severity. Monitoring these shifts via single-cell analysis of biopsy samples could complement traditional histological assessments.
  2. Understanding Disease Pathogenesis: The distinct cellular profiles of 'Inflamed' versus 'Healthy' and the heterogeneity within 'Non-inflamed' provide a foundation for understanding the underlying cellular mechanisms driving colonic inflammation. For instance, the prominent B cell expansion in some samples could indicate a significant role for humoral immunity in specific forms of colitis.
  3. Targeted Therapies: Identifying the immune cell populations that significantly expand during inflammation (e.g., B cells, specific T cell subsets) could guide the development of more targeted therapies. For example, B cell-depleting therapies or strategies to modulate macrophage function might be considered if these cell types are identified as key drivers of pathology in a subset of patients.
  4. Defining Remission and Treatment Response: The variability in 'Non-inflamed' samples highlights the challenge in defining complete remission. Further investigation into the immune cell profiles of 'Non-inflamed' samples that still show elevated immune populations could help distinguish true histological remission from clinical remission where subclinical inflammation persists. This could lead to more refined treatment goals and monitoring strategies.

5. T cell and Innate Lymphoid Cell Subpopulation Analysis in Colonic Inflammation

Report figure

[Analysis Visualization Results]...

Analysis Overview

This analysis presents population bar plots illustrating the relative proportions of T cell and Innate Lymphoid Cell (ILC) subsets within individual samples, grouped by their assigned health condition: Healthy, Inflamed, and Non-inflamed. The data is derived from single-cell RNA-seq of human colon tissue, and the visualization allows for a direct comparison of immune cell composition across different inflammatory states. The primary goal is to identify shifts in these immune cell populations that may be associated with colonic inflammation.

Visual Summary

The visualization displays the proportional composition of various immune cell subsets, including different T helper cell types, cytotoxic T cells, naive T cells, NK cells, and various ILC subtypes (ILC1, ILC2, ILC3 (NCR+), ILC3 (NCR-), ILCreg, LTI), for each sample.

Biological Interpretation

The observed shifts in T cell and ILC populations are highly consistent with the immunological landscape of colonic inflammation.

  1. ILC Expansion in Inflammation: The most striking feature is the proportional expansion of various ILC subsets (ILC1, ILC2, ILC3) in inflamed and some non-inflamed samples. ILCs are critical innate immune cells residing in mucosal tissues like the colon, acting as early responders to pathogens and tissue damage. Their expansion suggests an active, rapid innate immune response initiating or propagating inflammation.
    • ILC1s: Associated with type 1 immunity, producing IFN-gamma, which promotes a pro-inflammatory environment characteristic of certain forms of colitis PubMed search: ILC1 colitis.
    • ILC2s: Involved in type 2 immunity, secreting cytokines like IL-5 and IL-13, typically linked to allergic inflammation or helminth infections, but also play complex roles in tissue repair and chronic inflammation in the gut PubMed search: ILC2 colon inflammation.
    • ILC3s: Produce IL-17 and IL-22, essential for maintaining gut barrier integrity and host defense against extracellular bacteria, but can also contribute to chronic inflammation in dysregulated states PubMed search: ILC3 inflammatory bowel disease. The increase in ILC3s suggests an altered gut epithelial response or microbial interaction in inflamed conditions.
  2. T Cell Dynamics: While ILCs expand, the relative proportions of T cell (Naive) and T cell (Cytotoxic) appear to be diluted in inflamed contexts. This could indicate recruitment, differentiation, or a relative decrease compared to the expanding ILC population. The persistent presence of T cell (Th1) and T cell (Th17) subsets in inflamed tissue is expected, as these are well-established drivers of chronic inflammation in the gut, such as in inflammatory bowel disease (IBD). T cell (Treg) presence across all conditions underscores their essential role in immune homeostasis and the attempt to modulate inflammation.
  3. Heterogeneity in "Non-inflamed" Samples: The variability within the "Non-inflamed" group, with some samples resembling "Inflamed" profiles, is biologically significant. This might represent areas of the colon that are not overtly inflamed histologically but are already undergoing immune activation or have residual inflammatory signatures due to chronic disease. This highlights the importance of single-cell resolution to detect subclinical immune alterations.

Clinical or Translational Implications

These findings have several potential clinical and translational implications for understanding and managing colonic inflammation:

6. T cell Subset Population Shifts in Colonic Inflammation

Report figure

[Analysis Visualization Results]...

Analysis Overview

This analysis presents box plots visualizing the proportional representation of various T cell subsets (Th2, Th1, Th17, Treg, Tfh, and Cytotoxic T cells) across three distinct colonic conditions: Inflamed, Non-inflamed, and Healthy. The aim is to identify statistically significant differences in the proportions of these key immune cell populations between conditions, thereby providing insights into T cell dynamics during colonic inflammation. A p-value cutoff of 0.1 was applied to determine statistical significance for pairwise comparisons.

Visual Summary

The box plots reveal several statistically significant shifts in T cell subset proportions:

Biological Interpretation

The observed changes in T cell subset proportions offer critical insights into the immune landscape of colonic inflammation:

Clinical or Translational Implications

These findings highlight distinct T cell immune profiles associated with colonic inflammation and could have several clinical implications:

---

References:

  1. IL-17 and Th17 cells in autoimmune disorders.

PubMed Search: IL-17 Th17 autoimmune review

  1. IL-22 in gut immunity and inflammation.

PubMed Search: IL-22 gut immunity inflammation review

  1. Regulatory T cells in gut homeostasis and inflammation.

PubMed Search: Regulatory T cells gut homeostasis inflammation review

  1. Follicular helper T cells in inflammatory bowel disease.

PubMed Search: Tfh cells inflammatory bowel disease

  1. Therapeutic targeting of Th17 cells.

PubMed Search: Th17 therapeutic targeting review

7. Macrophage Subset Population Shifts in Colonic Inflammation

Report figure

[Analysis Visualization Results]...

Analysis Overview

This analysis presents a population bar plot illustrating the relative proportions of different macrophage subsets within the colon across 'Healthy', 'Inflamed', and 'Non-inflamed' conditions. The 'celltype_minor' level for macrophages has been further resolved into 'celltype_subset' (M1, M2A, M2B, M2C, M2D) to examine shifts in macrophage polarization states associated with colonic inflammation. Each bar represents a distinct biological sample, and the stacked segments within each bar show the percentage contribution of each macrophage subset.

Visual Summary

The bar plots reveal distinct patterns in macrophage subset distribution across the different conditions:

Biological Interpretation

Macrophages are highly plastic immune cells that play critical roles in both the initiation and resolution of inflammation. They can differentiate into distinct functional phenotypes, broadly categorized as pro-inflammatory M1-like macrophages and anti-inflammatory/pro-resolving M2-like macrophages.

The observed increase in Macrophage (M1) populations in the 'Inflamed' colon samples strongly suggests a prominent pro-inflammatory immune response. M1 macrophages are typically activated by microbial products (e.g., LPS) and T helper 1 (Th1) cytokines like IFN-gamma. They are characterized by their ability to produce pro-inflammatory cytokines (e.g., TNF-alpha, IL-6, IL-1beta) and reactive oxygen/nitrogen species, which are crucial for pathogen clearance but can also contribute to tissue damage in chronic inflammation like colonic inflammation [NCBI].

Conversely, the relative decrease in M2-like macrophage subsets, such as M2A and M2D, in the 'Inflamed' state indicates a shift away from tissue repair and immunosuppressive functions. M2 macrophages are generally associated with the resolution of inflammation, wound healing, angiogenesis, and dampening immune responses through the production of anti-inflammatory cytokines (e.g., IL-10, TGF-beta) [NCBI]. The reduced presence of these subsets in inflamed tissue might suggest an ongoing inflammatory process that is failing to resolve or an overwhelming pro-inflammatory environment.

This polarization imbalance towards M1 macrophages is a hallmark of many inflammatory diseases, including inflammatory bowel disease (IBD), which involves chronic colonic inflammation.

Clinical or Translational Implications

The findings highlight the critical role of macrophage polarization in colonic inflammation:

8. Macrophage (M2B) Subset Population Dynamics in Colonic Inflammation

Report figure

[Analysis Visualization Results]...

Analysis Overview

This analysis investigates the proportional changes of the Macrophage (M2B) subset across different conditions in human colon tissue: Healthy, Non-inflamed, and Inflamed. The box plots display the celltype proportion, with individual data points overlaid, and indicate statistically significant differences between conditions using p-values. The objective is to identify how the abundance of this specific macrophage subset is modulated during colonic inflammation.

Visual Summary

The box plot illustrates the celltype proportion of Macrophage (M2B) cells.

Biological Interpretation

Macrophages are critical immune cells with diverse functions in tissue homeostasis, immunity, and inflammation. M2 macrophages are generally associated with anti-inflammatory, pro-resolving, tissue repair, and immune regulatory functions. The M2B subtype, in particular, can be involved in immune suppression, antigen presentation, and, in some contexts, can also contribute to inflammation or fibrosis.

The observed increase in Macrophage (M2B) cell proportions in both Non-inflamed and Inflamed conditions compared to the Healthy colon suggests a robust involvement of this specific macrophage subset in the inflammatory response.

Clinical or Translational Implications

The findings suggest several potential clinical implications for colonic inflammation:

9. Cell-Cell Interaction Patterns in Healthy, Inflamed, and Non-inflamed Colon

Report figure

[Analysis Visualization Results]...

Analysis Overview

This analysis presents cell-cell interaction (CCI) patterns, identified using CellPhoneDB, across three conditions: Healthy, Inflamed, and Non-inflamed colon tissue. The results are visualized as dot plots, where each dot represents a specific ligand-receptor pair between two cell types. The size of the dot indicates the statistical significance (-log10(p-value)), and the color indicates the interaction strength (log2(mean expression)). This allows for a comparative assessment of the molecular communication landscape between cell types under different physiological states related to colonic inflammation. The analysis focuses on identifying key ligand-receptor interactions that are altered or dominant in the inflamed state, offering insights into disease mechanisms and potential therapeutic targets.

Visual Summary

The dot plots illustrate distinct cell-cell interaction profiles across Healthy, Inflamed, and Non-inflamed conditions in the colon.

Biological Interpretation

The observed cell-cell interaction patterns provide critical insights into the molecular mechanisms driving colonic inflammation.

  1. Pro-inflammatory Signaling via Prostaglandins: The highly significant and strong ProstaglandinE2_byPTGES2_PTGER4 interactions, especially involving Macrophages and Intestinal Epithelial cells in the 'Inflamed' condition, underscore the central role of Prostaglandin E2 (PGE2) in mediating inflammation. PGE2 is a potent lipid mediator produced by cyclooxygenases (like PTGES2) and acts via specific G-protein coupled receptors (like PTGER4) to promote various aspects of inflammation, including vasodilation, pain, and immune cell modulation. This interaction suggests active pro-inflammatory feedback loops between macrophages, plasma cells, and epithelial cells during inflammation. PubMed: Prostaglandin E2 in inflammation
  2. Altered Epithelial-Immune and Epithelial-Stromal Communication:
    • The strong APP|PIGR interaction in 'Inflamed' between Intestinal Epithelial cells and T cells, and Fibroblasts and Epithelial cells, is notable. Amyloid Precursor Protein (APP) is involved in various cellular processes including cell adhesion, migration, and signaling, and can be modulated during inflammation. PIGR facilitates the transport of polymeric immunoglobulins across epithelial layers, contributing to mucosal immunity. An altered interaction could signify changes in epithelial barrier function or host defense. GeneCards: APP
    • The enhanced CEACAM5_CEACAM6 interactions in 'Inflamed' within the Intestinal Epithelial cell compartment and with Macrophages are significant. CEACAMs (Carcinoembryonic Antigen-related Cell Adhesion Molecules) are involved in cell adhesion, signaling, and can be upregulated in inflammatory bowel diseases and cancers. Their increased presence suggests altered epithelial integrity and heightened communication with immune cells, potentially impacting inflammatory responses. GeneCards: CEACAM5
  3. Immune Cell Activation and Survival:
    • The strong TNFSF13B_TNFRSF17 (BAFF-BAFFR) interactions involving Plasma cells in the 'Inflamed' condition highlight active B cell maturation and plasma cell survival pathways. BAFF (B-cell Activating Factor) is crucial for B cell homeostasis and its dysregulation is implicated in autoimmune and inflammatory diseases. This suggests robust humoral immune responses are active in the inflamed colon. GeneCards: TNFSF13B
    • The NAMPT_NOX2_complex interaction between Intestinal Epi|Macrophage in inflammation points to enhanced oxidative stress and immune activation. NAMPT (nicotinamide phosphoribosyltransferase) is an enzyme with cytokine-like properties that can induce inflammatory responses, and NOX2 is a component of NADPH oxidase, a major source of reactive oxygen species in macrophages, contributing to inflammation.
  4. Stromal-Immune Cell Crosstalk: The consistent presence of CXCL12_CXCR4 interactions within Fibroblasts and between Fibroblasts and other cells indicates its fundamental role in stromal cell function and immune cell recruitment. CXCL12 (stromal cell-derived factor-1) and its receptor CXCR4 are critical for leukocyte trafficking and stromal remodeling, which are profoundly affected in chronic inflammation. GeneCards: CXCL12 The TYROBP_CD44 interaction in Fibroblast|Macrophage in 'Inflamed' also points to specific communication axes between stromal and immune cells that could influence macrophage activation and tissue remodeling during inflammation.

Clinical or Translational Implications

The identified cell-cell interaction patterns offer promising avenues for therapeutic intervention and biomarker discovery in colonic inflammation.

Therapeutic Target Prioritization:

Biomarker Development:

Experimental Validation:

10. Cell-Cell Interaction Patterns in Colonic Inflammation

Report figure

[Analysis Visualization Results]...

Analysis Overview

This analysis utilizes CellPhoneDB to identify significant cell-cell interactions (CCIs) involving major tissue cells, immune cells, and stromal cells in human colon tissue across 'Healthy', 'Inflamed', and 'Non-inflamed' conditions. The results are presented as a dot plot, illustrating the strength and statistical significance of specific ligand-receptor interactions for each sample within each condition. The primary goal is to highlight CCIs that differ significantly between conditions, shedding light on potential mechanisms underlying colonic inflammation. The analysis focused on major cell types: T cell, Myeloid cell, B cell, Mast cell, Intestinal Epithelial cell, Stromal cell, and Endothelial cell, with a maximum of 60 top interactions per group selected based on minimum p-value.

Visual Summary

The dot plot visualizes a comprehensive landscape of cell-cell interactions, with samples grouped by condition (Healthy, Inflamed, Non-inflamed) on the y-axis and specific CCI pairs on the x-axis. The color intensity of each dot represents the scaled log strength of the interaction (darker red indicates stronger interaction), while the size of the dot reflects its statistical significance (-log10(p-value), larger dots indicate more significant interactions).

Biological Interpretation

The differential cell-cell interaction patterns observed in the inflamed colon provide critical insights into the underlying biological processes. The shift from a homeostatic network in the healthy colon to a highly active, inflammatory-driven network highlights key pathways involved in chronic inflammation, tissue remodeling, and immune cell recruitment.

General Trends in Inflammation

Key Inflamed-Condition Specific Interactions

Prostaglandin Signaling

Integrin-Mediated Adhesion & ECM Remodeling

Immune Cell Trafficking & Activation

Macrophage-driven Interactions

Epithelial Cell Interactions

Clinical or Translational Implications

The identified cell-cell interactions represent potential therapeutic targets for managing colonic inflammation. Modulating these interactions could offer novel strategies to resolve inflammation, prevent tissue damage, or reduce fibrotic complications.

Targeting Prostaglandin Signaling

Modulating Integrin-Mediated Adhesion and ECM Remodeling

Interfering with Immune Cell Trafficking (CXCL12-CXCR4 axis)

Targeting Pro-inflammatory Cytokine Signaling (TNF)

Modulating Macrophage Function (TREM2, CD52-SIGLEC10)

Restoring Epithelial Homeostasis (CEACAMs, Cholesterol Pathways)

11. Condition-Specific Surfaceome Markers in Intestinal Epithelial Cells During Colonic Inflammation

Report figure

[Analysis Visualization Results]...

Analysis Overview

This analysis identifies condition-specific surfaceome markers in Intestinal Epithelial cells (IECs) across Healthy, Inflamed, and Non-inflamed colonic tissue samples using single-cell RNA sequencing data. The dot plot visualizes the mean expression level (color intensity) and the fraction of cells expressing a marker (dot size) for selected surfaceome genes within each sample. Markers were identified by comparing each condition against a reference (either 'Healthy' or 'others'), applying cutoffs for non-zero percent score and fold change, and limiting to surfaceome proteins. The overarching goal is to identify potential therapeutic targets for Colonic Inflammation.

Visual Summary

The dot plot clearly segregates marker expression profiles based on the tissue condition:

Overall, the plot effectively visualizes a substantial reprogramming of the IEC surfaceome in response to inflammation, with significant upregulation of immune-related and adhesion molecules, and downregulation of certain homeostatic transporters.

Biological Interpretation

The differential expression of surfaceome markers in Intestinal Epithelial cells during colonic inflammation provides critical insights into the pathological mechanisms and potential therapeutic targets. The changes reflect altered immune interactions, barrier function, and cellular signaling within the inflamed colon.

Markers Upregulated in Inflamed Intestinal Epithelial Cells

  1. Major Histocompatibility Complex (MHC) Molecules and Associated Proteins

References:

References:

  1. Adhesion Molecules and Barrier Function Modulators

References:

References:

References:

References:

  1. Immune Modulators and Transporters

References:

References:

Markers Upregulated in Healthy Intestinal Epithelial Cells (and Downregulated in Inflammation)

  1. Anion Exchangers Critical for Intestinal Homeostasis

References:

Clinical or Translational Implications

The identified surfaceome markers in Intestinal Epithelial cells during colonic inflammation offer several promising avenues for clinical and translational applications:

  1. Biomarker Discovery: The differentially expressed surfaceome markers, particularly those highly upregulated in inflamed IECs (e.g., HLA-DRB1, CD74, CEACAM5, MUC13), could serve as specific diagnostic or prognostic biomarkers for colonic inflammation. These could be detected via tissue biopsy, or potentially through non-invasive means if shed forms are present.
  2. Therapeutic Targets:
    • Immune Modulation: Upregulation of MHC molecules (HLA-DRB1, HLA-DRA) and CD74 highlights the IECs' active role in local immune responses. Targeting the CD74-MIF axis could offer a strategy to dampen inflammation.
    • Epithelial Barrier Enhancement: Disruption of the epithelial barrier is central to colonic inflammation. Markers like MUC1/MUC13, ITGB1/ITGA6, and DSG2, which are critical for barrier function and adhesion, could be targets. Strategies could aim to either reduce the expression/activity of pro-inflammatory mucins (e.g., MUC13) or enhance the function of adhesion molecules to promote wound healing and barrier integrity.
    • Ion Transport Regulation: The significant downregulation of homeostatic transporters like SLC26A3 in inflamed tissue, coupled with upregulation of SLC12A2, contributes to symptoms like diarrhea. Restoring SLC26A3 function or inhibiting SLC12A2 could alleviate secretory diarrhea and improve overall gut health.
  3. Drug Development: Surfaceome proteins are highly desirable drug targets as they are accessible to antibodies or small molecules without needing to cross the cell membrane.
    • Antibody-based therapies: Monoclonal antibodies against specific upregulated surface markers (e.g., CD74, CEACAM5, certain integrins) could selectively target inflamed IECs, potentially delivering therapeutics or modulating receptor function.
    • Small molecule inhibitors/modulators: Developing small molecules to inhibit pro-inflammatory signaling (e.g., via CD74-MIF) or restore epithelial transporter function (e.g., SLC26A3) presents attractive therapeutic opportunities.
  4. Stratification of Patients: The specific patterns of marker expression might help in stratifying patients based on their inflammatory profiles, enabling more personalized treatment approaches. For instance, patients with high expression of specific immune-modulatory surface markers might respond better to certain biologics.

These findings underscore the critical role of Intestinal Epithelial cells as active participants in the inflammatory process and not just passive victims of immune attack, opening new avenues for understanding and treating colonic inflammation.

12. Macrophage Condition-Specific Surfaceome Markers in Colonic Inflammation

Report figure

[Analysis Visualization Results]...

Analysis Overview

This analysis identifies condition-specific surfaceome markers for Macrophage cells in human colon tissue, comparing Healthy, Inflamed, and Non-inflamed states. The dot plot visualizes the mean expression level (color intensity) and the fraction of cells expressing (dot size) for selected surface markers across individual samples within each condition. The markers were selected based on differential expression comparisons against the 'Healthy' reference, with criteria including nz_pct_score and nz_pct_FC. The aim is to understand macrophage activation states and identify potential therapeutic targets in the context of colonic inflammation.

Visual Summary

The dot plot reveals distinct patterns of macrophage surface marker expression across the three conditions: Healthy, Inflamed, and Non-inflamed.

Biological Interpretation

The differential expression of these surfaceome markers provides insights into the functional shifts of macrophages during colonic inflammation.

Markers Enriched in Healthy Macrophages

  1. HLA-DQB1:
    • Associated Signaling/Mechanism: HLA-DQB1 is a major histocompatibility complex (MHC) class II molecule, critical for presenting exogenous antigens to CD4+ T cells. In healthy tissues, its expression on macrophages supports immune surveillance and the maintenance of immune tolerance to commensal microbiota and dietary antigens in the gut.
    • Role in Colonic Inflammation: The observed downregulation of HLA-DQB1 in macrophages from Inflamed and Non-inflamed conditions suggests a potential shift in macrophage function away from conventional antigen presentation to CD4+ T cells. This could imply a less tolerogenic or a more specialized effector macrophage phenotype in inflamed contexts, or a general suppression of MHC II machinery under inflammatory stress.
    • Therapeutic Potential: While not a direct therapeutic target for suppression, understanding the factors leading to HLA-DQB1 downregulation could reveal mechanisms by which inflammatory macrophages alter adaptive immune responses.
  2. ITM2C:
    • Associated Signaling/Mechanism: ITM2C (Integral Membrane Protein 2C) is part of a family of transmembrane proteins with diverse roles, including cell adhesion, protein processing, and potentially immune function, though its exact mechanisms in macrophages are less thoroughly characterized compared to canonical immune markers. Its high expression in healthy macrophages suggests a role in maintaining macrophage homeostasis or specific interactions in a non-inflamed environment.
    • Role in Colonic Inflammation: Its reduced expression in Inflamed and Non-inflamed conditions could indicate a disruption of homeostatic macrophage functions or a phenotype switch.
    • Therapeutic Potential: Limited as a primary therapeutic target due to nascent understanding of its specific immune mechanisms.

Markers Upregulated in Inflamed and Non-inflamed Macrophages

These markers point towards a widespread activation of macrophages in both inflamed and seemingly "non-inflamed" tissue segments, suggesting a chronic or pre-inflammatory state in the latter.

  1. CLEC7A (Dectin-1):
    • Associated Signaling/Mechanism: CLEC7A is a C-type lectin receptor, primarily known for recognizing β-glucans from fungi and certain bacteria. Upon ligand binding, it activates intracellular signaling pathways (e.g., Syk kinase) leading to phagocytosis, reactive oxygen species (ROS) production, and cytokine release (e.g., IL-1β, IL-6, TNF-α), thereby orchestrating innate immune responses and influencing adaptive immunity UniProt: Q9Y2W6.
    • Role in Colonic Inflammation: Upregulation of CLEC7A signifies an enhanced capacity of macrophages to sense and respond to microbial components. In colonic inflammation, this increased recognition of gut microbes can drive significant pro-inflammatory responses, contributing to tissue damage.
    • Therapeutic Potential: Modulating Dectin-1 activity could be beneficial. Antagonists could dampen excessive inflammatory responses to commensal microbiota in conditions like Inflammatory Bowel Disease (IBD), while agonists might be useful in enhancing anti-fungal immunity if specific infections are present.
    • Therapeutic Agents: Research is ongoing for specific Dectin-1 modulators; some small molecules and antibodies are in preclinical development.
  2. CYBB (NOX2):
    • Associated Signaling/Mechanism: CYBB (Cytochrome B-245 Beta Chain) is the catalytic subunit of the NADPH oxidase complex (NOX2), which generates superoxide radicals (ROS). This "oxidative burst" is crucial for microbial killing within phagosomes and serves as an important signaling molecule in inflammatory pathways GeneCards: CYBB.
    • Role in Colonic Inflammation: The upregulation of CYBB indicates increased oxidative stress and ROS production by macrophages. While essential for host defense, excessive or prolonged ROS generation in the colon can lead to oxidative tissue damage, epithelial barrier dysfunction, and perpetuation of chronic inflammation, a key feature of inflammatory bowel diseases.
    • Therapeutic Potential: Inhibiting NOX2 activity could reduce oxidative stress and inflammation.
    • Therapeutic Agents: NADPH oxidase inhibitors, such as apocynin or specific small molecule inhibitors (e.g., GKT137831), are being investigated in various inflammatory conditions, including preclinical models of IBD PubMed search: NADPH oxidase inhibitors IBD.
  3. FCGR2A (CD32a):
    • Associated Signaling/Mechanism: FCGR2A is an activating Fc gamma receptor (FcγRIIa) expressed on myeloid cells. It binds to the Fc region of IgG antibodies, leading to various effector functions such as phagocytosis, antigen presentation, and the release of pro-inflammatory cytokines, typically upon engagement by immune complexes UniProt: P12318.
    • Role in Colonic Inflammation: Elevated FCGR2A expression suggests an enhanced capacity of macrophages to respond to immune complexes, which are often abundant in inflamed colonic tissue. This can amplify and perpetuate inflammatory cascades by triggering macrophage activation and cytokine secretion, contributing to chronic inflammation.
    • Therapeutic Potential: Blocking or modulating FCGR2A activity could reduce immune complex-driven inflammation.
    • Therapeutic Agents: Strategies to inhibit FcγR signaling are being explored in autoimmune and inflammatory diseases to mitigate immune-mediated pathology.
  4. CD86:
    • Associated Signaling/Mechanism: CD86 is a co-stimulatory molecule (B7-2) expressed on antigen-presenting cells (APCs), including macrophages. It interacts with CD28 on T cells, providing a crucial second signal for T cell activation, proliferation, and differentiation. It also binds CTLA-4 on T cells, which delivers an inhibitory signal GeneCards: CD86.
    • Role in Colonic Inflammation: Upregulation of CD86 signifies macrophage activation and an enhanced ability to activate T cells. In the inflamed colon, this heightened co-stimulation can drive pathogenic T cell responses, contributing to the chronic immune activation characteristic of IBD.
    • Therapeutic Potential: Blocking the CD86-CD28 co-stimulation pathway can suppress T cell activation and subsequent inflammation.
    • Therapeutic Agents: Abatacept (CTLA4-Ig), a fusion protein that binds to CD80 and CD86, thereby preventing CD28 co-stimulation, is an approved therapy for certain autoimmune diseases. Similar strategies could be explored in colonic inflammation to temper pathological T cell responses.

Clinical or Translational Implications

The distinct expression profiles of macrophage surface markers across Healthy, Inflamed, and Non-inflamed colonic tissues offer valuable insights for diagnostics and therapeutic development in colonic inflammation.

Therapeutic Targets:

13. Fibroblast Condition-Specific Surfaceome Markers in Colonic Inflammation

Report figure

[Analysis Visualization Results]...

Analysis Overview

This analysis identifies condition-specific surfaceome markers in Fibroblast cells from human colon tissue across Healthy, Inflamed, and Non-inflamed conditions. The results are presented as a dot plot, showing the mean expression level (color intensity) and the fraction of cells expressing the marker (dot size) for each gene across individual samples grouped by condition. The markers were selected based on differential expression criteria comparing each condition against the 'Healthy' reference, with a focus on surfaceome genes. This provides insights into the distinct surface protein profiles of fibroblasts in different inflammatory states, which can inform our understanding of their biological roles and identify potential therapeutic targets in colonic inflammation.

Visual Summary

The dot plot displays the expression patterns of 20 surfaceome markers in Fibroblast cells across various samples categorized as Healthy, Inflamed, and Non-inflamed.

Biological Interpretation

The observed upregulation of specific surfaceome markers in fibroblasts from Inflamed and Non-inflamed colonic tissues provides critical insights into their role in colonic inflammation. Fibroblasts are crucial stromal cells that maintain tissue structure, but in chronic inflammatory diseases like Inflammatory Bowel Disease (IBD), they become activated, contributing to both inflammatory processes and fibrogenesis.

The prominent markers identified in activated fibroblasts suggest several key biological mechanisms at play:

Extracellular Matrix (ECM) Remodeling and Adhesion:

Fibroblast Activation and Proliferation:

Inflammatory Signaling and Immune Cell Recruitment:

Other Notable Markers:

The distinct marker profile in Inflamed fibroblasts reflects their transition into an activated, pro-inflammatory, and pro-fibrotic state. The similar, albeit often less pronounced, pattern in Non-inflamed samples suggests that even macroscopic "non-inflamed" areas in affected individuals may harbor fibroblasts with an altered, possibly primed or chronically activated, phenotype.

Clinical or Translational Implications

The identification of condition-specific surfaceome markers on fibroblasts provides significant clinical and translational opportunities, particularly for Colonic Inflammation and its associated complications, such as fibrosis and stricture formation in IBD.

  1. Biomarkers for Disease Activity and Fibrosis:
    • The robust upregulation of markers like PDGFRA, THY1, IL6ST, VCAM1, and ITGB1 could serve as diagnostic or prognostic biomarkers for assessing fibroblast activation, disease severity, and the risk of fibrosis in colonic inflammation. These surface markers could potentially be detected via imaging techniques (e.g., PET tracers targeting specific receptors) or by analyzing fibroblast populations directly from tissue biopsies.
  2. Therapeutic Targets for Colonic Inflammation and Fibrosis:
    • PDGFRA: As a key driver of fibroblast proliferation and ECM production, PDGFRA is an attractive anti-fibrotic target. Inhibitors specific to PDGFRA could reduce fibroblast expansion and collagen deposition, thereby mitigating fibrosis and stricture formation in chronic colonic inflammation. Tyrosine kinase inhibitors with PDGFRA activity (e.g., imatinib, though broad-spectrum) have been explored in various fibrotic diseases. More fibroblast-specific PDGFRA inhibitors could be developed.
    • IL6ST: By acting as a common signaling component for multiple pro-inflammatory cytokines, IL6ST presents a broad target to dampen inflammation and fibrosis. Blocking IL6ST signaling on fibroblasts could reduce their pro-inflammatory and pro-fibrotic responses, potentially offering a novel approach beyond direct cytokine neutralization.
    • VCAM1: Its critical role in immune cell recruitment makes VCAM1 a highly relevant therapeutic target to reduce inflammation. While systemic VCAM1 blockade carries risks, fibroblast-specific targeting or modulating VCAM1 expression specifically on colonic fibroblasts could be a strategy to limit immune cell infiltration without broad systemic immunosuppression. Existing anti-integrin therapies (e.g., vedolizumab, which targets α4β7 integrin) demonstrate the principle of blocking adhesion molecules to treat IBD.
    • THY1 and ITGB1: These markers reflect fibroblast activation and ECM interaction. Targeting THY1-positive activated fibroblasts directly (e.g., with antibody-drug conjugates) or modulating ITGB1-mediated adhesion could interfere with fibroblast pro-fibrotic functions and reduce tissue remodeling, thereby preventing or reversing fibrosis.
  3. Understanding "Non-inflamed" Disease States:
    • The observation that fibroblasts in "Non-inflamed" tissue still exhibit an activated phenotype highlights the importance of targeting underlying stromal cell pathology even in areas of apparent quiescence. This suggests that disease activity might persist at a cellular level, contributing to disease relapse or progression towards complications. Therapeutic strategies might need to consider this persistent fibroblast activation.

These surface markers offer the potential for developing highly specific, fibroblast-targeted therapies that could modulate the inflammatory and fibrotic microenvironment in the colon, leading to more effective treatments with reduced off-target effects.

14. Condition-Specific Surfaceome Markers in Colonic CD4+ T Cells

Report figure

[Analysis Visualization Results]...

Analysis Overview

This analysis investigates the differential expression of surfaceome markers on CD4+ T cells across Healthy, Inflamed, and Non-inflamed colon tissue samples. The goal is to identify markers that distinguish these conditions, particularly those potentially involved in colonic inflammation, and explore their biological roles and therapeutic implications. The dot plot visualizes the mean expression (color intensity) and the fraction of cells expressing (dot size) for selected surface markers in each individual sample, clustered by condition.

Visual Summary

The dot plot displays the expression patterns of several surface markers (EMP3, LY6E, CD7, PTPRC, KLRB1, CD44, CD27, IL7R, CD3G) across individual samples grouped into Healthy, Inflamed, and Non-inflamed categories.

Key observations include:

Upregulation in Inflamed and Non-inflamed Conditions:

Downregulation in Inflamed and Non-inflamed Conditions:

Variable or Less Pronounced Changes:

Overall, the plot highlights several surface markers that are dynamically regulated on CD4+ T cells in the context of colonic inflammation, suggesting shifts in T cell activation, differentiation, and tissue homing properties.

Biological Interpretation

The observed changes in surfaceome marker expression in CD4+ T cells offer insights into their altered states in colonic inflammation:

  1. LY6E (Lymphocyte Antigen 6 Family Member E): Upregulation of LY6E in inflamed CD4+ T cells suggests their activation and potential involvement in inflammatory processes. LY6E is a GPI-anchored protein known to modulate T cell receptor (TCR) signaling, proliferation, and migration. Its heightened expression could contribute to sustained T cell activation and effector functions within the inflamed colon.
  2. CD44 (CD44 Molecule): The pronounced upregulation of CD44 is a classic indicator of T cell activation and memory formation. CD44, a receptor for hyaluronic acid and other extracellular matrix components, facilitates T cell adhesion to endothelial cells, extravasation into inflamed tissues, and retention within these sites. Its overexpression signifies active immune cell trafficking and responsiveness to the inflammatory microenvironment.
    • Signaling Pathways: Upon ligand binding, CD44 activates pathways involving Rho GTPases and ERM proteins, crucial for cytoskeletal reorganization and cell migration. It also influences PI3K/Akt and MAPK pathways, impacting T cell survival and proliferation.
    • References: CD44 (GeneCards), PubMed search: "CD44 T cell inflammation"
  3. KLRB1 (Killer Cell Lectin Like Receptor B1 / CD161): The increased expression of KLRB1 on a subset of CD4+ T cells in inflamed and non-inflamed conditions suggests the expansion of specific T cell subsets. CD161+ CD4+ T cells have been associated with Th17 differentiation and have complex roles in chronic inflammation, sometimes acting as effector cells and other times having regulatory functions. Its expression marks a distinct T cell population potentially contributing to gut immunopathology.
    • Signaling Pathways: KLRB1 contains an ITIM-like motif, typically mediating inhibitory signals by recruiting phosphatases (e.g., SHP-1/2). However, in certain contexts, it can also provide co-stimulatory signals, influencing overall T cell activation.
    • References: KLRB1 (GeneCards), PubMed search: "CD161 T cell inflammation"
  4. EMP3 (Epithelial Membrane Protein 3): While less characterized in T cell immunology, the observed upregulation of EMP3 suggests its involvement in the altered cellular state of CD4+ T cells during colonic inflammation. As a membrane protein, EMP3 has been implicated in cell growth, differentiation, and apoptosis in other contexts. Its specific function in activated T cells in the colon warrants further investigation.
    • Signaling Pathways: Direct signaling pathways involving EMP3 in T cells are not well-established, but its presence may influence membrane dynamics or interact indirectly with known signaling cascades.
    • References: EMP3 (GeneCards)
  5. IL7R (Interleukin 7 Receptor / CD127): The downregulation of IL7R on CD4+ T cells in inflamed and non-inflamed conditions is a common feature of effector or highly activated T cells. Loss of IL7R expression indicates reduced responsiveness to IL-7, a critical cytokine for T cell survival and homeostasis. This pattern suggests that these T cells have undergone significant activation and differentiation, moving away from a naive/memory resting state towards an effector phenotype.
  6. CD7 and CD27: While showing some differential patterns, their changes are less striking or consistent compared to LY6E, CD44, KLRB1, and IL7R. CD7 is involved in T cell activation and adhesion, while CD27 is a co-stimulatory TNF receptor family member important for T cell survival and memory. Their variable expression might reflect heterogeneous activation and differentiation states within the CD4+ T cell population during inflammation.

Clinical or Translational Implications

The identified surfaceome markers in CD4+ T cells hold significant potential as biomarkers and therapeutic targets for Colonic Inflammation:

Biomarkers of Disease Activity/Prognosis:

Therapeutic Targets for Colonic Inflammation:

Further functional studies are warranted to precisely elucidate the mechanistic roles of these differentially expressed surface markers in CD4+ T cells within the context of colonic inflammation, paving the way for targeted therapeutic interventions.

15. Gene Ontology (GSA) Analysis for Intestinal Epithelial Cells in Colonic Conditions

Report figure

[Analysis Visualization Results]...

Analysis Overview

This analysis presents Gene Ontology (GSA) results for Intestinal Epithelial cells, focusing on pathways enriched by up-regulated differentially expressed genes (DEGs). The results are depicted as bar plots showing statistical significance (-log(p-value) and -log(q-value)) for various biological terms. Three comparisons are shown: "Healthy_vs_others" (Healthy vs. Inflamed + Non-inflamed), "Inflamed_vs_Healthy", and "Non-inflamed_vs_Healthy". The goal is to identify distinct biological processes active in intestinal epithelial cells under different colonic conditions, particularly in the context of inflammation.

Visual Summary

GSA for Intestinal Epithelial cell: Healthy_vs_others (Based on up-regulated DEGs)

The top enriched pathways in healthy Intestinal Epithelial cells, when compared to all other conditions, are primarily metabolic. Highly significant terms include "Diabetic cardiomyopathy," "Non-alcoholic fatty liver disease," "Oxidative phosphorylation," "Parkinson disease," "Thermogenesis," "Huntington disease," "Citrate cycle (TCA cycle)," "Fatty acid degradation," and various other pathways related to lipid, carbohydrate, and amino acid metabolism (e.g., "Pyruvate metabolism," "Valine, leucine and isoleucine degradation," "Glycolysis / Gluconeogenesis"). This suggests a robust basal metabolic state and energy production capacity in healthy epithelial cells.

GSA for Intestinal Epithelial cell: Inflamed_vs_Healthy (Based on up-regulated DEGs)

In the inflamed condition compared to healthy, Intestinal Epithelial cells show a profound upregulation of pathways related to cellular stress, protein synthesis, processing, and degradation. The most significantly enriched terms include "Protein processing in endoplasmic reticulum," "Ribosome," "Spliceosome," "Ubiquitin mediated proteolysis," and "Proteasome." A prominent feature is the activation of numerous infection-related pathways, such as "Coronavirus disease," "Viral carcinogenesis," "Shigellosis," "Pathogenic Escherichia coli infection," "Salmonella infection," "Antigen processing and presentation," and various viral infections (e.g., "Human T-cell leukemia virus 1 infection," "Hepatitis C," "Influenza A," "Human cytomegalovirus infection"). Cell cycle, apoptosis, and "Tight junction" pathways are also notably enriched, along with inflammatory signaling like "TNF signaling pathway" and some cancer-related pathways.

GSA for Intestinal Epithelial cell: Non-inflamed_vs_Healthy (Based on up-regulated DEGs)

Similar to the inflamed state, Intestinal Epithelial cells in the non-inflamed condition (compared to healthy) also exhibit upregulation of protein processing, synthesis, and stress response pathways, including "Protein processing in endoplasmic reticulum," "Ribosome," "Spliceosome," and "Ubiquitin mediated proteolysis." Many infection-related pathways are also enriched, such as "Coronavirus disease," "Viral carcinogenesis," "Shigellosis," "Salmonella infection," and "Bacterial invasion of epithelial cells," though generally with lower statistical significance (especially in q-value) compared to the "Inflamed_vs_Healthy" comparison. Cellular processes like "Cell cycle," "Longevity regulating pathway," and "Tight junction" are also identified.

Biological Interpretation

  1. Metabolic Homeostasis in Healthy Epithelium: Healthy Intestinal Epithelial cells are characterized by high metabolic activity, particularly in oxidative phosphorylation, carbohydrate, and lipid metabolism. This is consistent with their crucial role in nutrient absorption, high cellular turnover, and maintaining the energy demands of the intestinal barrier. The unexpected presence of neurodegenerative disease pathways might reflect shared metabolic or stress response components rather than specific neuronal function in the colon.
  2. Robust Stress and Immune Response in Inflamed Epithelium: During inflammation, Intestinal Epithelial cells dramatically upregulate pathways for protein synthesis, folding, degradation, and transport. This indicates intense cellular activity, likely involved in repairing damage, producing inflammatory mediators, and mounting a defense. The strong enrichment of various bacterial and viral infection pathways, along with "Antigen processing and presentation" and "Phagosome," highlights the epithelial cells' active role as frontline defenders against microbial challenges in the inflamed colon. The upregulation of "Tight junction" components could represent an attempt to restore or reinforce the compromised epithelial barrier [1]. The activation of "TNF signaling pathway" is a direct link to inflammatory cascades.
  3. Subclinical Perturbation in Non-inflamed Epithelium: The "Non-inflamed" state, while lacking overt inflammation, demonstrates a molecular profile that deviates significantly from healthy. These cells show an activation of many stress response, protein processing, and infection-related pathways similar to those seen in inflamed cells, albeit typically with reduced statistical significance. This suggests that even in the absence of macroscopic inflammation, these epithelial cells are under stress or are reacting to subtle challenges, possibly indicating a subclinical inflammatory process, an early disease state, or a chronic perturbation that has not yet escalated to full-blown inflammation. This "non-inflamed" state is not truly quiescent but actively responding to environmental cues.

Clinical or Translational Implications

---

References:

[1] Review on tight junctions in inflammation: PubMed Search: "intestinal epithelial tight junction inflammation"

[2] Review on inflammation and colorectal cancer: PubMed Search: "colonic inflammation colorectal cancer risk"

16. Gene Set Enrichment Analysis (GSEA) Across Colon Cell Types in Inflammatory Conditions

Report figure

[Analysis Visualization Results]...

Analysis Overview

This analysis presents Gene Set Enrichment Analysis (GSEA) results visualized as a dot plot. The analysis compares gene expression rankings in various colon cell types across different conditions (Inflamed, Non-inflamed) against a 'Healthy' reference, as well as 'Healthy' against other conditions. The goal is to identify biological pathways and processes that are significantly altered in different states of colonic inflammation. The plot displays 120 key gene sets/pathways (Y-axis) for each cell type-condition comparison (X-axis). Dot color indicates the Normalized Enrichment Score (NES), where red signifies positive enrichment (generally upregulated pathways) and blue signifies negative enrichment (generally downregulated pathways) in the 'test' condition compared to the 'reference'. Dot size represents the statistical significance (-log(p-value)).

Visual Summary

The dot plot reveals widespread and significant alterations in gene set enrichment across nearly all examined cell types, particularly when comparing Inflamed_vs_Healthy.

Biological Interpretation

The GSEA results provide comprehensive insights into the molecular mechanisms underpinning colonic inflammation.

  1. Hallmarks of Inflammation: The robust and widespread enrichment of "IL-17 signaling pathway" (a cytokine central to autoimmune and inflammatory diseases), "TNF signaling pathway" (a key mediator of inflammation), and "Toll-like receptor signaling pathway" (critical for innate immune recognition of pathogens) unequivocally points to a highly activated inflammatory response in the colon. This activation is not restricted to immune cells but extends to structural cells like Intestinal Epithelial cells and Endothelial cells, highlighting their active participation in the inflammatory cascade PubMed: 35179477.
  2. Immune Cell Activation and Function:
    • Antigen Presentation: Strong enrichment of "Antigen processing and presentation" in B cells, Dendritic cells, Macrophages, and Intestinal Epithelial cells in the inflamed state suggests active engagement of adaptive immunity.
    • T-cell Polarization: Enrichment of "Th1 and Th2 cell differentiation" and "Th17 cell differentiation" in T cell CD4+ and CD8+ populations indicates a strong adaptive immune response with diverse T helper cell subsets contributing to the inflammatory milieu.
    • Leukocyte Trafficking: "Leukocyte transendothelial migration" enrichment, particularly in Endothelial cells and various immune cells, indicates increased immune cell infiltration into the inflamed tissue, a defining feature of inflammation.
  3. Tissue Damage, Remodeling, and Repair:
    • The dysregulation of "Cell cycle", "DNA replication", "Apoptosis", and "Necroptosis" pathways across multiple cell types suggests ongoing cellular stress, damage, and attempts at repair or regeneration, characteristic of chronically inflamed tissues.
    • "HIF-1 signaling pathway" (hypoxia-inducible factor) and "VEGF signaling pathway" (vascular endothelial growth factor) enrichment points to potential hypoxic conditions and active angiogenesis, crucial for maintaining blood supply and tissue remodeling in chronic inflammation GeneCards: HIF1A, GeneCards: VEGFA.
    • Changes in "Adherens junction" and "Tight junction" pathways, especially in Intestinal Epithelial cells, imply compromised intestinal barrier integrity, a known feature in inflammatory bowel diseases PubMed: 35898393.
  4. Metabolic Reprogramming: The alterations in metabolic pathways (e.g., glycolysis, arginine metabolism) indicate that cells in the inflamed microenvironment undergo significant metabolic shifts to meet the energetic demands of inflammation, proliferation, and defense. This metabolic reprogramming can sustain immune cell activation and influence disease progression.
  5. Microbial Interactions: Enrichment of pathways related to various bacterial infections (e.g., *Salmonella*, *Shigella*) suggests that host responses to microbial components or dysbiosis play a significant role. This does not necessarily imply active infection by these specific pathogens but rather the activation of immune pathways typically engaged during such infections, which can be triggered by the altered gut microbiome in inflammation.
  6. Enteric Glial Cell Involvement: The observation that Enteric glial cells also show enrichment in inflammatory and infection-related pathways indicates a broader involvement of the enteric nervous system in modulating gut inflammation, pointing towards neuro-immune interactions.

Clinical or Translational Implications

The comprehensive GSEA findings offer several potential clinical and translational implications for colonic inflammation:

  1. Therapeutic Targets: The consistent and strong activation of pathways like IL-17, TNF, and Toll-like receptor signaling across multiple cell types reinforces their importance as established and potential therapeutic targets. Existing biologics often target TNF (e.g., infliximab, adalimumab) or IL-17 (e.g., secukinumab, ixekizumab), and these results support their relevance in this context PubMed search: TNF alpha inhibitors inflammatory bowel disease, PubMed search: IL-17 inhibitors inflammatory bowel disease. Targeting components of the Toll-like receptor signaling pathway or downstream effectors could also be considered.
  2. Biomarker Discovery: The specific enrichment patterns in different cell types could aid in identifying novel cell-type-specific biomarkers for diagnosing, prognosticating, or monitoring treatment response in colonic inflammation. For instance, specific metabolic pathway shifts or immune cell activation markers identified in this analysis could serve as diagnostic indicators.
  3. Understanding Chronic Disease Progression: The dysregulation of cell cycle, apoptosis, and tissue remodeling pathways highlights the chronic nature of the disease and mechanisms that could lead to complications like fibrosis or altered tissue architecture. Interventions targeting these pathways could potentially mitigate long-term damage.
  4. Personalized Medicine: The cell-type-specific nature of pathway enrichment suggests that therapeutic strategies might need to be tailored to target the most affected cell populations or pathways in individual patients, moving towards a more personalized approach to treating colonic inflammation.
  5. Dietary and Microbiome Interventions: Given the strong signal for infection-related pathways and the known role of the microbiome in colonic inflammation, this analysis indirectly supports the potential for dietary interventions or microbiome modulation as complementary therapeutic strategies to manage inflammation PubMed: 36838384.

17. Discussion

The single-cell analysis of human colon tissue provides a comprehensive view of the cellular and molecular reprogramming that occurs during inflammation. The UMAP visualizations clearly demonstrate condition-specific clustering, with significant shifts in cellular composition marked by prominent immune cell infiltration and altered proportions in inflamed tissues. Notably, T cell and Innate Lymphoid Cell (ILC) populations undergo significant changes, with an expansion of ILC1, ILC2, and ILC3 subsets, alongside an increase in pro-inflammatory Th17 cells and immunoregulatory Treg cells, while Th1 and Th2 cell proportions decrease. Macrophages show a distinct polarization towards a pro-inflammatory M1-like phenotype in inflamed conditions, indicative of their active role in driving pathology.

Beyond immune cell dynamics, non-immune cell populations such as Intestinal Epithelial Cells (IECs) and Fibroblasts emerge as active participants in the inflammatory milieu. IECs in inflamed contexts exhibit a robust upregulation of MHC Class I and II molecules (HLA-DRB1, HLA-DRA), co-stimulatory molecules (CD74), and adhesion molecules (CEACAM5, MUC13, ITGB1/ITGA6), suggesting enhanced antigen presentation capabilities and altered barrier function. Conversely, homeostatic transporters (SLC26A3) are downregulated. Fibroblasts transition to an activated, pro-inflammatory, and pro-fibrotic state, characterized by elevated expression of PDGFRA, THY1, IL6ST, and VCAM1, actively contributing to extracellular matrix remodeling and immune cell recruitment.

Cell-cell interaction (CCI) analyses unveil a profoundly reshaped communication network in the inflamed colon. Key upregulated interactions include ProstaglandinE2-PTGER4 signaling, integrin-mediated adhesion to the ECM, CXCL12-CXCR4 for immune cell trafficking, TNF-TNFRSF for pro-inflammatory cytokine signaling, and BAFF-BAFFR for plasma cell survival. These interactions highlight the intricate crosstalk between immune, epithelial, and stromal cells, collectively driving and sustaining inflammation. Gene Ontology (GSA) and Gene Set Enrichment Analysis (GSEA) consistently corroborate these cellular observations, demonstrating widespread activation of pathways related to IL-17 signaling, TNF signaling, Toll-like receptor signaling, antigen processing, leukocyte transendothelial migration, and metabolic reprogramming across nearly all cell types in the inflamed state. Interestingly, epithelial cells in inflammation show robust activation of protein processing, stress response, and infection-related pathways, alongside an attempt to reinforce tight junctions.

A particularly notable and recurrent finding across multiple analyses is the 'Non-inflamed' condition. This state consistently presents an intermediate phenotype that significantly deviates from 'Healthy' tissue, often sharing molecular signatures with 'Inflamed' samples, albeit with attenuated intensity. This is observed in minor cell type population shifts (especially B cells and ILCs), T cell and macrophage subset proportions (M2B increase), CCI patterns, and the surfaceome marker profiles of IECs, macrophages, and fibroblasts, as well as in epithelial GSA and global GSEA results. This suggests that 'Non-inflamed' regions in diseased individuals are not truly quiescent but harbor subtle, persistent immune activation, cellular stress, or a lingering memory of past inflammatory episodes. This challenges traditional histological classifications and underscores the importance of single-cell resolution for detecting subclinical disease activity or a 'pre-inflammatory' state that could contribute to disease progression or relapse. The consistent activation of common inflammatory pathways across immune and non-immune cells in both inflamed and non-inflamed contexts provides strong evidence for a tissue-wide pathological environment, rather than localized immune infiltrates.

Hypotheses:

  1. Persistent immune activation and cellular reprogramming in 'Non-inflamed' colonic tissue contribute to disease recurrence or progression.
  2. Dysregulated prostaglandin signaling and specific integrin-mediated interactions between macrophages, fibroblasts, and epithelial cells are central drivers of chronic inflammation and fibrosis in the colon.
  3. Intestinal Epithelial Cells actively contribute to perpetuating colonic inflammation through enhanced antigen presentation and altered barrier function, rather than being merely passive victims.
  4. The observed metabolic reprogramming across various cell types in the inflamed colon fuels sustained immune responses and contributes to tissue pathology.

Potential therapeutic targets:

  1. PTGER4 (Prostaglandin E2 Receptor 4): Highly significant and strong interactions involving Prostaglandin E2, especially between Macrophages, Plasma cells, and Intestinal Epithelial cells in the inflamed colon, indicate a central role for PGE2 in mediating pro-inflammatory signaling. PTGER4 is a key receptor for PGE2. Evidence: CCI dot plots (Images 9, 10, 11, 12) show strong ProstaglandinE2_byPTGES2_PTGER4 interactions, particularly in 'Inflamed'. GSA for IECs (Image 17, 18, 19) shows 'TNF signaling pathway' enrichment, often downstream of PGE2, reinforcing the inflammatory context. Validation: In vitro assays using PTGER4 antagonists on primary colon cells (macrophages, IECs) from inflamed patients to measure reduction in pro-inflammatory cytokine secretion (e.g., TNF-α, IL-6) and restoration of barrier function. In vivo validation in murine models of colitis using genetic deletion or pharmacological inhibition of PTGER4.
  2. CD74 or MIF (Macrophage Migration Inhibitory Factor): CD74 is significantly upregulated on Intestinal Epithelial Cells in the inflamed state and mediates pro-inflammatory signaling upon binding MIF, a cytokine often elevated in IBD. Blocking this interaction could dampen epithelial-driven inflammation. Evidence: Dot plot of IEC surfaceome markers (Image 13) shows high expression of CD74 in 'Inflamed' IECs. GSA for IECs (Image 17, 18, 19) shows enrichment for infection and inflammatory pathways where MIF plays a role. Validation: Antibody-mediated blockade of CD74 or MIF in IEC/macrophage co-culture systems to assess reduction in inflammatory responses. In vivo studies in murine colitis models with CD74 or MIF inhibitors.
  3. PDGFRA (Platelet-Derived Growth Factor Receptor Alpha): PDGFRA is highly expressed on activated fibroblasts in both inflamed and non-inflamed conditions, indicating their proliferative and pro-fibrotic state. Inhibiting PDGFRA could reduce fibroblast expansion and ECM production, mitigating fibrosis. Evidence: Dot plot of Fibroblast surfaceome markers (Image 15) shows high expression of PDGFRA in 'Inflamed' and 'Non-inflamed' fibroblasts. Validation: In vitro assays with PDGFRA inhibitors on primary colon fibroblasts from IBD patients to measure reduction in proliferation, collagen production, and migration. In vivo validation in fibrotic colitis models.
  4. CD86 (B7-2) or CD28 (on T cells): CD86 is significantly upregulated on macrophages in both inflamed and non-inflamed conditions, indicating enhanced capacity to activate T cells. Blocking CD86-CD28 co-stimulation can suppress pathogenic T cell responses. Evidence: Dot plot of Macrophage surfaceome markers (Image 14) shows high expression of CD86 in 'Inflamed' and 'Non-inflamed' macrophages. GSEA (Image 20) shows enrichment for 'T cell receptor signaling pathway' and 'Th1 and Th2 cell differentiation' pathways in T cells in inflamed conditions, which are dependent on CD86-CD28 interaction. Validation: In vitro co-culture of patient-derived macrophages and T cells with CD86 blocking antibodies or CTLA4-Ig fusion proteins to assess T cell proliferation and cytokine production. In vivo studies in immune-mediated colitis models.

Follow-up validation ideas:

  1. Spatial Transcriptomics/Multiplex Imaging: To confirm the spatial localization and co-localization of activated immune cells (e.g., Th17, Treg, M1 macrophages) and activated stromal/epithelial cells (e.g., PDGFRA+ fibroblasts, MHC II+ IECs) in inflamed and non-inflamed tissue sections. This would validate CCI findings in situ.
  2. Flow Cytometry/Immunohistochemistry on Clinical Biopsies: To validate the proportional shifts of T cell and macrophage subsets (e.g., Th17, Treg, M2B) and surface marker expression (e.g., CD44, LY6E on T cells; CLEC7A, CD86 on macrophages; PDGFRA, VCAM1 on fibroblasts; CEACAM5, HLA-DRB1 on IECs) in larger patient cohorts, correlating with disease activity and response to therapy.
  3. In vitro Co-culture Systems: To functionally test key cell-cell interactions. For example, co-culture of primary colon fibroblasts with macrophages or T cells from inflamed donors, with specific ligand/receptor blocking antibodies (e.g., anti-PTGER4, anti-VCAM1, anti-CD86) to assess impacts on cytokine production, cell migration, and activation.
  4. Organoid/Ex-vivo Colon Culture Models: To investigate the impact of inflammatory stimuli (e.g., TNF-α, IL-17, bacterial PAMPs) on epithelial barrier function (e.g., tight junction integrity, SLC26A3 expression) and cell-cell communication with embedded immune or stromal cells.
  5. Targeted Perturbation Assays: Using gene editing (CRISPR/Cas9) in colon-derived cell lines or organoids to perturb key genes (e.g., IL6ST, PDGFRA in fibroblasts; CLEC7A, CYBB in macrophages; CD74, MUC13 in IECs) and assess functional consequences on inflammatory responses, proliferation, or barrier integrity.
  6. Metabolomic Profiling: Perform targeted or untargeted metabolomics on inflamed vs. healthy colon tissue samples to validate the observed metabolic reprogramming from GSEA and GSA results.

Limitations:

This analysis relies on cross-sectional single-cell RNA-seq data, which, while providing a detailed snapshot of cellular states, limits the ability to infer causality or track disease progression over time. The 'Non-inflamed' samples, identified as molecularly distinct from 'Healthy' but resembling 'Inflamed' in several aspects, highlight the challenge of precisely classifying disease states and warrant further in-depth clinical and functional characterization to distinguish subclinical inflammation from remission or other perturbed states. Cell-cell interaction predictions are based on ligand-receptor expression and require experimental validation to confirm functional significance. Finally, therapeutic targets are nominated based on differential expression and pathway enrichment, and their efficacy and specificity in a clinical setting would necessitate rigorous experimental and clinical validation to confirm their mechanistic roles and therapeutic utility.

18. Query List

  1. Show and save UMAPs for condition, sample, major cell type, minor cell type, and celltype_subset in two columns.
  2. Show major cell type scores on UMAP and save the result.
  3. Show and save a marker expression dot plot for celltype_subset. SET target_cell = None and var_group_rotation = 45. Leave all other arguments at their default values.
  4. Show and save a population bar plot of minor cell types.
  5. Show and save a population bar plot of T cell subsets.
  6. Show and save box plots of T cell subset populations with statistically significant differences between conditions, if any. Choose ncols based on the total number of panels.
  7. Show and save a population bar plot of macrophage subsets.
  8. Show and save box plots of macrophage subset populations with statistically significant differences between conditions, if any. Choose ncols based on the total number of panels.
  9. Show and save cell-cell interaction patterns. Select at most 80 cell-cell interactions per group.
  10. Find cell-cell interactions involving major tissue cells, immune cells and stromal cells that differ significantly between conditions, show them as a dot plot, and save the result. Set max_n_items_per_group to 60. For each interaction identified under each condition, using the provided dataset context, describe the associated signaling pathways and mechanisms and, where relevant, its potential as a therapeutic target and related therapeutic agents.
  11. Show marker expressions for Intestinal Epithelial cells in a dot plot, and save the result. Use only surfaceome markers, with at most 50 markers per condition. For each marker identified under each condition, using the provided dataset context, describe the associated signaling pathways and biological mechanisms within the tissue and, where relevant, its potential as a therapeutic target for Colonic Inflammation and related therapeutic agents.
  12. Show marker expressions for Macrophage in a dot plot, and save the result. Use only surfaceome markers, with at most 40 markers per condition. For each marker identified under each condition, using the provided dataset context, describe the associated signaling pathways and biological mechanisms within the tissue and, where relevant, its potential as a therapeutic target for Colonic Inflammation and related therapeutic agents.
  13. Show marker expressions for Fibroblast in a dot plot, and save the result. Use only surfaceome markers, with at most 40 markers per condition. For each marker identified under each condition, using the provided dataset context, describe the associated signaling pathways and biological mechanisms within the tissue and, where relevant, its potential as a therapeutic target for Colonic Inflammation and related therapeutic agents.
  14. Show marker expressions for T cell CD4+ in a dot plot, and save the result. Use only surfaceome markers, with at most 40 markers per condition. For each marker identified under each condition, using the provided dataset context, describe the associated signaling pathways and biological mechanisms within the tissue and, where relevant, its potential as a therapeutic target for Colonic Inflammation and related therapeutic agents.
  15. Show Gene Ontology (GSA) analysis results for Intestinal Epithelial cells as a bar plot, and save the result.
  16. Show Gene Set Enrichment Analysis results as a dot plot, and save it. Set the color map to RdBu_r, n_pws_to_show to 120, and target_cells to None.
Top